China / Decentralised & Digitalised: Patient-Centric DCTs
Writing in the special December 2022 edition of DIA’s Global Forum magazine – which focuses exclusively on decentralised clinical trials – on behalf of the DIA China Digital Health Community…
Address: Room 301,E unit, 3rd Building,Helicon Garden (Hongjialiyuan), Haidian District,Beijing 100088,China
Tel: (86-10)82050626
Formed in May 1988, the purpose of CNMA is to promote and raise the level of research, production and sales management of the Chinese OTC industry in compliance with social ethics and the relevant laws, regulations and policies.
CNMA represents the members’interests and submits policy advices to the concerned government departments on drugs’ classification, OTC research, production and sale.
CNMA also provides the members with consulting, training and information services to promote OTC technology, enhance OTC quality and ensure the consumers’ safety in using OTC products.
Another key role is to raise the knowledge and awareness about self-medication and OTC products. CNMA also organizes different activities to strengthen cooperation and contacts with international organizations, OTC associations and enterprises.
Industry Regulation and Coordination, Education
Writing in the special December 2022 edition of DIA’s Global Forum magazine – which focuses exclusively on decentralised clinical trials – on behalf of the DIA China Digital Health Community…
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021:…
A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR…
Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up…
China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential…
Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR…
Writing in the May edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk China looks at the new drug approvals in China in 2021. Among other highlights, the…
Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D…
See our Cookie Privacy Policy Here
